Late-breaking abstracts explore cardiovascular outcomes of patients with anemia in chronic kidney disease ( CKD ) treated with roxadustat, including associations with achieved hemoglobin levels and risk of Major Adverse Cardiovascular Events ( MACE ) and MACE+
Full Story >>
Vote
+16